TTI1 antibody is a research tool designed to target the TTI1 protein, a component of the conserved Triple T (TTT) complex (composed of TTI1. TTI2. and TELO2). The TTT complex plays a critical role in maintaining cellular homeostasis by stabilizing and regulating the PI3K-related kinase (PIKK) family members, including ATM, ATR, mTOR, and DNA-PKcs. These kinases are essential for DNA damage response, cell cycle control, and metabolic signaling. TTI1 acts as a scaffolding protein, facilitating proper folding, stability, and activation of PIKKs. Dysregulation of TTI1 or the TTT complex has been linked to genomic instability, cancer progression, and neurodegenerative disorders.
The TTI1 antibody is widely used in molecular biology to investigate TTI1 expression, localization, and interactions via techniques like Western blotting, immunofluorescence, and co-immunoprecipitation. It aids in studying TTI1’s role in stress responses, DNA repair mechanisms, and mTOR signaling pathways. Researchers also utilize TTI1 antibodies to explore its potential as a biomarker or therapeutic target in diseases associated with PIKK dysfunction. Commercial TTI1 antibodies are typically validated for specificity in human, mouse, or rat models, with applications spanning basic research and translational studies in oncology and neurology.